The current five-fold increased risk of SIEs in AQP4+ patients, compared to the MOG+ group, may likely partly be related to co-morbid rheumatic disease, and associated treatments, which was absent in MOG+ patients. This evidence concerns the gene AQP4 and rheumatic disorder.